{"entity":{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","aka":[],"tldr":"Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease.","summary":"Gabriel Hortobagyi has run breast cancer trials at MD Anderson for four decades and was principal investigator of MONALEESA-2, which showed ribociclib plus letrozole improves progression-free and then overall survival in postmenopausal HR-positive advanced breast cancer. He has chaired ASCO and helped write the AJCC staging system for breast cancer. His work continues on endocrine resistance and adjuvant CDK4/6 inhibition.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hortobagyi%20GN%5BAuthor%5D%20ribociclib"}],"tags":["breast","trialist"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["cdk46-inhibitor"],"targets":["cdk4-6"],"drugs":["ribociclib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["monaleesa-2","natalee"],"people":[],"bottlenecks":[],"keyPapers":["paper-natalee-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Breast cancer","CDK4/6 inhibitors","Endocrine therapy","Neoadjuvant therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hortobagyi%20GN%5BAuthor%5D%20ribociclib"}],"papers":[{"title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer (MONALEESA-2)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1609709"},{"title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2114663"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"}],"orcid":"0000-0002-4873-4412"},"route":"/people/gabriel-hortobagyi/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"}],"drug":[{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/"},{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/"}],"paper":[{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/"}]}}